Latest Innovation News

Invion Limited’s partner Hanlim Pharm, backed by South Korea’s government grant, has secured up to A$2 million in non-dilutive funding to advance preclinical studies of HL270 for oesophageal cancer, paving the way for human trials in Australia.

Adisyn Ltd has completed a strategic review, deciding to boost investment in its graphene-based semiconductor arm while exploring options to unlock value from its managed IT services business.

Saluda Medical has received CE certification for its EVA™ Sensing Technology, enabling commercialisation in Europe and recognition in Australia following prior FDA approval. This milestone sets the stage for a broader rollout of its personalised spinal cord stimulation therapy in early 2026.

Lithium Universe Limited has completed the second tranche of its share placement, raising $40,000 and issuing over 56 million listed options, as it pushes forward with lithium refinery projects in Québec and Texas.

TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.

Altamin Limited has completed a $1.003 million placement, bolstering its financial position to progress key projects in Italy amid ongoing permitting and partnership efforts.

Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.

Beetaloo Energy’s Carpentaria-5H well has delivered one of the highest gas flow rates in the Beetaloo Basin, showcasing promising long-term productivity and paving the way for pilot gas sales in 2026.

Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.

FlexiRoam has secured a strategic partnership with Generali Insurance Malaysia to deploy its AI-driven eSIM connectivity platform through WhatsApp, targeting the growing travel insurance market.

Aurizon has lodged a proposed ten-year Network Access Undertaking with the Queensland Competition Authority, aiming to secure long-term certainty and enhanced operational incentives for the Central Queensland Coal Network.

INOVIQ Limited has reported compelling preclinical results for its CAR-NK-exosome therapy targeting triple-negative breast cancer, showing significant tumor reduction and perfect survival in treated mice.